June 2022
Always an Option:
Clinical Trials for Kidney Cancer Patients
Will you need early access to new drugs at some point in your care? NOW is the time to start learning about clinical trials and when they might be right for you.

Clinical Trials Town Hall
Tuesday, July 19th
6:00-7:00 pm ET
Free Webinar via Zoom
Trial candidates include patients starting their first treatment, or patients who have progressed through many treatment options. The first step is having this conversation with your oncologist. Only about half of all kidney cancer patients report having a trial suggested as an option. All trial participants need to be well-informed participating members of the treatment team.
Join us for an hour and start learning and thinking about clinical trials. Register now to get your questions about trials on the list for our experts to address during the live, interactive option.
Top kidney cancer oncologists Brian Rini of Vanderbilt University and Elizabeth Plimack of Fox Chase Cancer Center will discuss clinical trials and answer registrants' questions on trials with information that could open new options for your future care. 
Check Out Our New YouTube Playlist!
KidneyCANDID Video
We've launched an exciting new video project called KidneyCANDID. KidneyCANDID is a YouTube video series where we explore topics for patients, caregivers, researchers, and clinicians.

We're sharing quick, informal videos created by those who live and deal with kidney cancer every day.

YouTube is the internet's fastest-growing search engine, with more than 210 million Americans using it to find information online in 2022. We want those in our community to find research news, inspiring stories, and helpful tips when they are looking for information about kidney cancer.
District Days in August:
Join Us to Ask for Lifesaving Research Funding
We need you to tell Congress to fund kidney cancer research. We've celebrated increased funding in recent years, but this sad fact remains: we're not finding cures fast enough for everyone.

On August 8-9, our delegates will meet with their representatives all over the country to help Congress understand the urgency and ask for funding. We'd like YOU to join us!

No experience necessary. We will train you and give you all the support you need to do a great job!
As part of our funding requests, we're asking Congress to support the CONNECT for Care Act, which expands telehealth options for patients across state lines. This is especially important for those in our community who travel to access specialized care they can't get at home.
Are you following us online? Tag @KidneyCAN
in your #kidneycancer posts!
KidneyCAN Community Spotlight:
Dr. Brandon Manley of Moffitt Cancer Center
For this month’s Community Spotlight, KidneyCAN spoke to Dr. Brandon Manley of Moffitt Cancer Center. In addition to his clinical responsibilities as a urologic oncologist, Dr. Manley engages in translational kidney cancer research as part of a team of physicians and scientists at Moffitt Cancer Center..

Dr. Manley shares his experiences as an advocate for research funding and what inspires him on hard days.
"We cannot be satisfied with the current standard of care."
- Brandon Manley, M.D.
We Need to Talk About Clinical Trials:
2022 World Kidney Cancer Day
June 16th was World Kidney Cancer Day, a day when the global kidney cancer community comes together to raise awareness of key issues facing kidney cancer patients and their caregivers around the world. 

Studies by the International Kidney Cancer Coalition (IKCC) show that many kidney cancer patients aren’t aware of the treatment options that may be available to them and don’t discuss them with their doctors nearly as often or as thoroughly as they should. 

Sometimes it’s because patients don’t feel they know enough or don’t feel they can question their doctors. Other times it’s because doctors don’t want to overwhelm their patients or their appointments are too short.

Here are six questions every patient should be able to ask their doctor. Save this for your next appointment!
Kidney Cancer Research Updates
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma
Brain metastases are a challenging manifestation of renal cell carcinoma. We have a limited understanding of brain metastasis tumor and immune biology, drivers of resistance to systemic treatment, and their overall poor prognosis.

Current data support a multimodal treatment strategy with radiation treatment and/or surgery. Nonetheless, the optimal approach for the management of brain metastases from renal cell carcinoma remains unclear. 

This is a great comprehensive guideline for management of brain mets in kidney cancer patients.
Research Presented at ASCO 2022:
A Summary for Patients
This year’s American Society of Clinical Oncology (ASCO) Annual Meeting was held both virtually and face-to-face from 3-7 June 2022. The presentations are available to view on the ASCO website.

The International Kidney Cancer Coalition (IKCC) reviewed the virtual scientific program to keep abreast of the latest advances in the care and treatment of patients with kidney cancer.

This is an outstanding summary of the research, presented in a patient-friendly format. Thank you to the IKCC for putting this article together for patients and caregivers.
We are busy planning the program for the 2022 Kidney Cancer Research Summit. You can register now to join us virtually as the world's leading kidney cancer researchers share the latest news and breakthroughs.
See the program of speakers and register now!
October 6-7, 2022
Our mission is to accelerate cures for kidney cancer. We engage in patient advocacy and power research by supporting government and industry research funding, facilitating research collaborations, and offering direct financial support for clinical and laboratory researchers with promising ideas. Our work is funded by grassroots donors from all over the United States. We can't do this without your support.
Thank you for being part of our grassroots army!
KidneyCAN is a registered 501(c)(3) nonprofit and does not receive any funding through the Congressionally Directed Medical Research Program (CDMRP) or KCRP (Kidney Cancer Research Program). KidneyCAN's work is funded entirely through donations.